Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MCOLN2 | Q8IZK6 | 2/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.47 |
| ▸ | MCOLN1 | Q9GZU1 | 2/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419813 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL6816353 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL810319 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| P-Xylene SCHEMBL5422459 | 0.98 | ALDH1A1 (0.60) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| P-Xylene SCHEMBL5421280 | 0.98 | ALDH1A1 (0.60) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL6055077 | 0.98 | ALDH1A1 (0.60) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL3499611 | 0.97 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| Benzene SCHEMBL5180862 | 0.96 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| Hexamethylbenzene SCHEMBL5424696 | 0.96 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E | |
| Benzene SCHEMBL5181252 | 0.96 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP3A4SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318260-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | claimed |
| EP-2187887-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2017-11-15 | — | — | EP | claimed |
| US-8575362-B2 | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | claimed |
| EP-2529740-A1 | Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds. | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-05 | — | — | EP | claimed |
| US-20110301349-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | TERSERA THERAPEUTICS LLC | 2011-12-08 | — | — | US | claimed |
| EP-2187887-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009029499-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | WO | claimed |
| EP-0915076-B1 | Process for the preparation of trans-(R,R)-actinol | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | EP | claimed |
| US-6187961-B1 | HYDROGENATING (R)-LEVODIONE IN PRESENCE OF HYDROGEN DONAR AND A SOLVENT OR IN PRESENCE OF HYDROGEN DONOR WHICH SIMULTANEOUSLY USED AS THE SOLVENT, AND AN AMINO-AMIDE-RUTHENIUM COMPLEX | ROCHE VITAMINS INC. | 2001-02-13 | — | — | US | claimed |
| CN-1223998-A | Process for producing trans- (R, R) -actinol | HOFFMANN LA ROCHE (CH) | 1999-07-28 | — | — | CN | claimed |
| EP-0915076-A1 | Process for the preparation of trans-(R,R)-actinol | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | claimed |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4115975-A1 | CATALYST CONTAINING ACTIVATED CARBON ON WHICH RUTHENIUM COMPLEX IS ADSORBED, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | Takasago International Corporation (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-3318260-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2018-04-05 | — | — | US | disclosed |
| WO-1997033588-A1 | IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997006830-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997006824-A2 | BIOCONJUGATES OF MANGANESE COMPLEXES AND THEIR APPLICATION AS CATALYSTS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0756495-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | RRS1, POR, SCO2 | ALDH1A1 492/4885TSHR 4343/4885CYP3A4 59/4885 |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CTRC, HAVCR2, HGFAC | ALDH1A1 4165/4885TSHR 3530/4885CYP3A4 52/4885 |
| US-20110301349-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | DPYD, TYMP, NUDT1 | ALDH1A1 490/4885TSHR 3411/4885CYP3A4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.